of course, an old standby - a suspension that over the years has had relatively uniform action. The same cannot be said of NPH. Supporters of this thesis will be pleased to learn that E.R. Squibb and Sons Ltd. have recently decided to provide globin zinc insulin, 100 U/ml, in Canada. Guy E. JORON, MD

3830 Lacombe Ave. Montreal, PQ

References 1. REINER L, SEARLE DS, LANG EH: Insulin preparations with prolonged activity: globin insulin. Proc Soc Exp Biol Med 40: 171, 1939 2. RABINOWITCH IM, FOWLER AF, BENSLEY EH. et al: Globin insulin. Can Med Assoc J 56:

595, 1947

Postpartum infection with meningococcemia To the editor: Attention has been drawn to the possibility of pathogenic Neisseria causing disease from unexpected body sites.1 The following is a case of meningococcemia associated with postpartum infection.

A 21-year-old woman, para 1, gravida I, came to the emergency department complaining of chills and fever 10 days after an uncomplicated vaginal delivery of a healthy baby boy. Physical examination revealed diffuse and extensive pelvic tenderness without purulent discharge from the cervix, a temperature of 39.8 0C and a pulse rate of 115 beats/mm. The patient was admitted with a provisional diagnosis of postpartum sepsis. The peripheral leukocyte count was 31.8 x 10./I (60% neutrophils, 27% bands). Gram-stained smears prepared from urine, cervix, vagina and episiotomy site provided no additional information. Two samples of blood were drawn for culture and the patient then received 4 million U of penicillin intravenously every 6 hours and 500 mg of kanamycin intravenously every 12 hours. Within 24 hours improvement was observed and her temperature decreased to 370C. The patient remained on this regimen for 4 days, then refused further intravenous therapy. Penicillin and kanamycin were replaced by ampicillin, 500 mg taken orally every 6 hours. On the 5th hospital day she discharged herself, leaving with enough ampicillin to complete a 10-day course. The two sets of blood cultures grew gram-negative diplococci in aerobic tubes after 5 days' incubation. Subsequently this organism was found to be oxidase-positive and to ferment both maltose and dextrose;

it was identified as Neisseria meningitidis, group C by immunodiffusion and counterimmunoelectrophoresis. All other cultures were negative for N. meningitidis.

The clinical features in this patient were consistent with those of classic postpartum infection, with isolation of an etiologic agent from blood. Rash,

meningitis or nasopharyngitis, which might have suggested N. meningitidis infection, was not present. Cervical culture did not yield N. meningitidis, but isolation of this organism from the genitourinary tract has been reported in seven patients with cervicitis or urethritis, although no systemic manifestations were recorded.2 Keys, Hecht and Chow3 reported two cases of fever, rash and joint involvement in which N. meningitidis was isolated from the endocervix. In one case the organism was recovered from blood and joint fluid. Pelvic infection was not a clinical feature of either case. Feldman1 has drawn attention to new patterns of gonococcal disease that are emerging with the increasing prevalence of gonorrhea and has suggested that the meningococcus is retaining its classic disease patterns. The association with postpartum infection is new for N. meningitidis and, furthermore, provides a rationale for the treatment of asymptomatic genital carriage of the organism, particularly in the pregnant patient. We are indebted to Dr. C. Krishnan, The Hospital for Sick Children, Toronto, for serotyping N. meningitidis.

JOHN R. MORGAN, PH D JACK FEDDER, MD, FACOG, FRCS[C] JOHN A. SMITH, MD, FRCP[C]

Mount Sinai Hospital Toronto, ON

References 1. FELDMAN HA: Meningococcus and gonococcus never the twain... well hardly ever. N Engi I Med 285: 518, 1971 2. CARPENTER CM, CHARLES R: Isolation of meningococcus from the gemtourinary tract of seven patients. Am I Public Health 32: 640, 1942 3. KEYS TF, HECHT RH, CHOW Aw: Endocervical N. meningitidis with meningococcaemia. N Engi I Med 285: 505, 1971

Standardization of tuberculin testing material To the editor: For many years a variety of materials have been available for tuberculin testing, including Old tuberculin of various strengths, patch tests, multiple puncture tests and, most recently, purified protein derivative of Old tuberculin (PPD). Consequently, results of epidemiologic studies and clinical interpretations have been varied and unreliable. In 1966, largely as a result of the work of Landi and colleagues,1 it was recognized that PPD solutions could lose up to 50% of their potency by adsorption of tuberculoprotein to the glass or plastic containers and syringes, and that this could be prevented by stabilization with polysorbate (Tween) 80, as had been done by Connaught Laboratories in Toronto for some years. At the request of the standards com-

294 CMA JOURNAL/FEBRUARY 21, 1976/VOL 114

mittee of the Canadian Thoracic Society a conference was held in Toronto attended by the leading authorities on the subject in Canada and the United States. Standardization of PPD at a strength bioequivalent to the stabilized standard PPD-S (5 tuberculin units [TU]), prepared at the Center for Disease Control, Atlanta, Georgia, was agreed to by the US authorities and by the minister of national health and welfare of Canada. Suitable labelling of the containers has been approved. The strength of the stabilized products issued by Connaught Laboratories, because it was not reduced by glass adsorption, had been approximately twice that of the standard solution used by the US Public Health Service. Now that the standard solutions used in the two countries are exactly comparable, results of previous epidemiologic surveys and standards of interpretation of skin testing remain valid. The Canadian Thoracic Society strongly recommends that tuberculin material for intradermal testing be a stabilized product bioequivalent to 5 TU of PPD (PPD-S). The correct interpretation of such a tuberculin test, read at 48 to 72 hours, is as follows: * 10 mm induration or more = positive. * 5 to 9 mm induration = doubtful. * 0 to 4 mm induration = negative. The use of solutions of 1, 10 or 250 TU in strength has little clinical or epidemiologic value except in certain circumstances. In future all dose strengths will refer to the stabilized solution, bioequivalent to PPD-S. The standards committee is now urging Health and Welfare Canada to approve exactly comparable standards for testing material for other mycobacteria, such as Battey bacilli. OWEN CLARKE, MD

Chairman, standards committee Canadian Thoracic Society 343 O'Connor St. Ottawa, ON

Reference 1. LANDI 5, HELD HR, HAUSCHILD AH, et al:

Adsorption of tuberculin PPD to glass and plastic surfaces. Bull WHO 35: 593, 1966

XYY phenotype; does it exist? To the editor: During the last year the group called Science for People succeeded in blocking and finally stopping at Harvard the survey of chromosomal errors in newborns. The discussion following this action appeared in several major scientific and medical journals and concerned the XYY phenotype. All chromosomal aberrations produce a wide range of severity of clinical symptoms. This is especially true of aberrations with extra or miss-

Atromid.S* (clofibrate) to lower blood lipids safely and effectively Indications ATROMID-S is indicated where reduction of blood lipids is desirable; e.g., patients with hypercholesterolemia and! or hypertriglyceridemia. Contraindlcatlons While teratogenic studies have not demonstrated any effect attributable to ATROMID-S, its use in nonpregnant women of childbearing age should only be undertaken in patients using strict birth control measures. If these patients then plan to become pregnant, the drug should be withdrawn several months before conception. The drug should not be given to lactating women. ATROMID-S is not recommended in children since, to date, an insufficient number of cases have been treated. ATROMID-S is not recommended for patients with impaired renal or hepatic function. Warning Caution should be exercised when anticoagulants are given in conjunction with ATROMID-S. The dosage of the anticoagulant should be reduced by one-third to one-half (depending on the individual case) to maintain the prothrombin time at the desired level to prevent bleeding complications. Frequent prothrombin determina'tions are advisable until it has been definitely determined that the levels have been stabilized. For PRECAUTIONS and ADVERSE REACTIONS, see scientific brochure. Dosage and Administration For adults only: One capsule (500 mg) four times daily. Availability No. 3243 Each capsule contains 500 mg clofibrate N.F. in bottles of 100 and 360. Further information, references, and scientific brochure available on request.

.

*

0

AYERST LABORATORIES, division of Ayerst, McKenna & Harrison Limited, Montreal, Canada Made in Canada by arrangement with IMPERIAL CHEMICAL INDUSTRIES LTD. Regd.

ing heterochromatic sex chromosomes; these aberrations are much less damaging than abnormalities of euchromatic autosomes (e.g., chromosome 21) and, therefore, for some cases the term "phenotype" would fit better than "syndrome". The main arguments put forward by this group1 have been these: antisocial behaviour in man is conditioned by socioeconomic and not by biologic (e.g., chromosomal) factors; no specific XYY syndrome exists; and XYY carriers found in prisons come from families of lower socioeconomic status, and their behaviour is a product of social deprivation. There are at least two ways of proving the existence of the XYY phenotype: either to identify the XYY individuals at birth and to follow their development (the method used at Harvard and criticized by Science for People) or to search for individuals who fit the putative phenotype description and to check the prevalence of the XYY karyotype in the sample. There is general agreement that the prevalence of this karyotype in an unselected male population is approximately 1:1000. If the XYY karyotype has no phenotypic effect this prevalence should be the same in every sample of the male population. Cytogenetic examination was conducted on patients admitted to Kingston Psychiatric Hospital between October 1974 and November 1975 who had symptoms corresponding to the putative XYY phenotype. Of five patients with these symptoms two were found to have the XYY karyotype; another XYY male was identified several years ago. All three patients (16 to 19 years of age) never had been in a penal institution, and never in a mental institution other than for examination. All were from stable families without criminality and none of their 12 siblings had behavioral problems. This was particularly true of family 1 (of five siblings two had graduated from university with honours) and even more so of family 3 (both parents had a university degree, and four siblings had been very successful in school, two of them having been on a dean's honour list). All three patients were of average intelligence; they were tall and had acne; their progress at school was poor; they manifested petty criminality and difficulty in controlling impulses (two of them had committed attacks with weapons); they were irresponsible and immature; and they had not held steady jobs. This is not surprising, because the patients were selected only according to the criteria just mentioned. However, another fact is surprising: if no XYY phenotype exists (as Science for People

claims), how can one explain the fact that the prevalence of XYY in our very small sample was 1:2.5, a remarkable increase from 1:1000? A chance occurrence only? This study was assisted under grant 26769 C of the Ontario Mental Health Foundation. D. SOUDEK, MD

Cytogenetics laboratory Kingston Psychiatric Hospital Queen's University Kingston, ON

Reference 1. BECEWITH J, KING J: XYY syndrome:

a

dangerous myth. New Scientist 64: 474, 1974

Insect-sting kits To the editor: I am engaged in the United States in what seems at times to be a one-man crusade, and I would like to bring it to the attention of Canadians. As an allergist I am acutely aware of the life-and-death situations that can be created by insect stings, and I know of several instances in which death could have been prevented if an emergency insect-sting kit had been available. We physicians give insect-sting kits to patients who need them, and we train them in their use. Yet people in positions of responsibility - school nurses or principals, forest rangers, scoutmasters, and others who may encounter people in allergic shock don't have the kits, nor do they know how to use them. Most state laws prohibit sales of such kits without a physician's prescription. I believe the laws should be changed so that persons in the kinds of positions indicated above, after receiving appropriate training, could purchase the kits without prescription. I hope others feel likewise and will be motivated to write their legislators to change the laws. I would appreciate hearing from other physicians who know of cases in which the use of an insect-sting kit could have prevented death. CLAUDE A. FRAZIER, MD

Doctor's Park Building 4-C Asheville, NC 28801 USA

[Readers are referred to the letter from Drs. Horan and Mandi in the Jan. 10, 1976 issue of the Journal (page 24) for a Canadian view of the treatment of insect-venom allergy. - Ed.] Canada's national sport To the editor: The well documented article "Eye injuries in Canadian hockey" (Can Med AssocJ 113: 663, 1975) opens its presentation with an oft-

CMA JOURNAL/FEBRUARY 21, 1976/VOL 114 297

Letter: XYY phenotype; does it exist?

of course, an old standby - a suspension that over the years has had relatively uniform action. The same cannot be said of NPH. Supporters of this the...
480KB Sizes 0 Downloads 0 Views